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Circulating levels of the thyroid hormones, triiodothyro-nine (T3) and thyroxine (T4), decrease substantially
during and after cardiopulmonary bypass (CPB).1-3
Possible responsible mechanisms include blood dilution
during CPB, alterations in peripheral T3 metabolism, and
central disruption of hypothalamic-pituitary-thyroid con-
trol induced by nonpulsatile flow.2,4 Regardless of the
operative mechanisms, depression of serum T3 and T4 lev-
els persists for several days after CPB in both adults and
children.3,5-7 Several investigators have postulated that
thyroid hormone deficiencies can contribute to myocar-
dial depression observed after cardiac surgery and CPB.
T3 or T4 supplementation after coronary artery bypass
Objective: Cardiopulmonary bypass suppresses circulating thyroid hormone
levels. Although acute triiodothyronine repletion has been evaluated in adult
patients after cardiopulmonary bypass, triiodothyronine pharmacokinetics
and effects have not previously been studied in infants undergoing opera-
tions for congenital heart disease. We hypothesized that triiodothyronine
deficiency in the developing heart after bypass may adversely affect cardiac
function reserve postoperatively. 
Methods: Infants less than 1 year old undergoing ventricular septal defect or
tetralogy of Fallot repair were randomized into 2 groups. Group T (n = 7)
received triiodothyronine (0.4 µg/kg) immediately before the start of car-
diopulmonary bypass and again with myocardial reperfusion. Control (NT,
n = 7) patients received saline solution placebo or no treatment.
Results: These groups underwent similar ischemic and bypass times and
received similar quantities of inotropic agents after the operation. The NT
group demonstrated significant depression in circulating levels, compared
with prebypass levels, for free triiodothyronine and total triiodothyronine at
1, 24, and 72 hours after bypass. Group T demonstrated similar low thyrox-
ine values, but free and total triiodothyronine levels were maintained at pre-
bypass levels for 24 hours and remained elevated over those of group NT 
(P < .05) at 72 hours. Heart rate was transiently elevated in group T com-
pared with group NT (P < .05), and peak systolic pressure-rate product
increased after 6 hours.
Conclusion: These data imply that (1) triiodothyronine in the prescribed dose
prevents circulating triiodothyronine deficiencies and (2) triiodothyronine
repletion promotes elevation in heart rate without concomitant decrease in
systemic blood pressure. Elevation of peak systolic pressure-rate product
implies that triiodothyronine repletion improves myocardial oxygen con-
sumption and may enhance cardiac function reserve after cardiopulmonary
bypass in infants. (J Thorac Cardiovasc Surg 2000;120:604-8)
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provides short-term increases in cardiac performance in
adults,2,3,8 which result from a direct inotropic effect on
the heart and decreases in systemic vascular resistance.3
The developing heart normally undergoes thyroid-
promoted maturation of physiologic and metabolic
processes, which can increase cardiac contractile func-
tion and reserve.9-13 However, operations for congenital
heart disease accompanied by CPB can theoretically
disturb this maturation at least temporarily by decreas-
ing circulating thyroid hormone levels. Thus, depres-
sion of thyroid hormone levels could limit cardiac con-
tractile responses during the vulnerable postoperative
period. Accordingly, we postulated that T3 repletion in
the immediate postoperative period should improve
hemodynamic parameters in infants undergoing cardiac
surgery with CPB. 
We designed a prospective randomized study to test
this hypothesis. This current study represents the initial
phase in evaluation of T3 repletion in infants undergo-
ing CPB. Acute hemodynamic responses, as well as
alterations in circulating thyroid hormone levels over
the first 24 postoperative hours, were examined. 
Methods
Patient selection. Extreme variability among anatomic
diagnoses is inherent to a population with congenital heart
disease and might confound analyses of data. This study was
designed to achieve relative uniformity in the patient popula-
tion and surgical procedures. Therefore, patients were eligible
for this study if they were less than 1 year of age and under-
went surgical repair of a perimembranous ventricular septal
defect, including those with tetralogy of Fallot. Patients with
pulmonary atresia or severe pulmonary artery hypoplasia
were excluded, as were those requiring additional surgical
procedures such as repair of coarctation of the aorta. The pro-
tocol and the consent form were approved by the institution-
al review board. All consent forms were signed by the
patient’s legal guardian.
Study design. Patients were randomized into 2 groups:
those receiving 2 doses of intravenous liothyronine (T3) 0.4
µg/kg before the start of CPB and immediately after release
of the aortic crossclamp (group T) and the control group
(group NT), which received a comparable volume of saline
solution. So that treatment bias would be limited, physicians
and staff primarily responsible for treating the patients post-
operatively, including nurses who recorded hemodynamic
data, were left unaware of group assignment. Hourly data
were extracted from intensive care flow sheets after patient
discharge from the intensive care unit by individuals blinded
to group assignment. A nurse practitioner, who was aware of
assignment, monitored the study for safety purposes. 
Thyroid hormone concentrations. Blood was obtained
before CPB and liothyronine administration and 1 hour, 24
hours, and 72 hours after CPB termination. Samples were ana-
lyzed for free T3, total T3, and total T4 at Endocrine Sciences
(Calabasas Hills, Calif). Total T3 and T4 levels were measured
by means of radioimmunoassays. Free T3 was measured by the
Riagnost 2-step manual protocol (Cis-US, Inc, Bedford, Mass). 
Pharmacokinetics of T3 supplementation.  Analysis was
performed to determine the serum half-life for exogenous free
T3 by means of a single compartmental model.14 Free T3 levels
in the placebo group were subtracted from free T3 levels in the
supplemented group to correct for the endogenous T3 levels. 
Hemodynamic parameters.  Patients’ hemodynamic para-
meters including heart rate and systolic and diastolic arterial
pressure were extracted from intensive care nursing sheets for
the initial 24-hour postoperative period. Hourly dosages of
inotropic drug support were also recorded for this time period. 
Statistical analyses. The StatView 4.5 (FPV) program
(1995, Abacus Concepts, Inc, Berkeley, Calif) was used for
statistical analyses. Data were evaluated with repeated-mea-
sures analysis of variance within groups and single-factor
analysis of variance between groups. When significant F val-
ues were obtained, individual group means were tested for
differences by means of the unpaired t test. 
Results
Patient characteristics. Diagnoses and surgical
parameters for the 2 groups are outlined in Table I.
There were no differences in age, CPB time, or aortic
crossclamp time between the 2 groups. 
Drug support. Dopamine or amrinone, or both, were
used for inotropic support in these patients. Two
patients from each group received identical doses of
amrinone through the 24-hour period. Mean dopamine
dose ranged between 1 to 3 µg · kg–1 · min–1 over the
24-hour period for each group. There were no signifi-
cant differences in dopamine requirement between the
groups (differences evaluated 1 and 6 hours after CPB
by the Wilcoxon test, P > .50).15 No other cate-
cholamine agonists were used. Two patients from each
group received identical doses of amrinone through the
24-hour period.
Thyroid hormone concentrations and pharmaco-
kinetics. Circulating thyroid hormone levels (free T3,
total T3, and total T4) are illustrated in Fig 1.
Concentrations for free and total T3 show a steady
Table I. Operative characteristics of patients
Parameters T3 group Control group
Age (days) 170 ± 80 190 ± 60*
Diagnosis
Ventricular septal defect 3 4
Tetralogy of Fallot 4 3
CPB time (min) 75 ± 31 91 ± 19*
Crossclamp time (min) 27 ± 6.5 28 ± 13.2*
Mean ± SD. 
*P > .2 for all comparisons. 
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decline and significant depression in the control group
through 72 hours, when levels reach about 50% of
baseline. Both free and total T3 levels were substantial-
ly higher in the treated group over the first 24 hours.
However, levels were similar to control values by 72
hours. T4 levels decreased significantly in both groups
at 1 hour, possibly due to an immediate dilutional effect
during CPB. Differences from baseline were apparent
in both groups at 72 hours as well. T3 administration
produced no T4 differences between groups at any
time. The number of longitudinal blood samples
obtained for determination of free T3 levels permitted
an approximation of serum half-life by means of the
described method at 16 hours. 
Hemodynamic data. Heart rate, systolic and dias-
tolic blood pressure, and peak pressure-rate product
(PRP) were generally maintained at steady levels in the
control group over the first 24 hours postoperatively
(Figs 2-4). In contrast, the treated group demonstrated
an increase in heart rate and PRP over time. Significant
differences in heart rate and PRP between groups were
demonstrated at 1 hour and 6 hours. Maximal elevation
in heart rate and PRP corresponded temporally with
peak T3 levels in the treated group. 
Adverse effects. A brief period of supraventricular
tachycardia occurred in 1 patient within group T. No
other adverse events that might be linked to T3 admin-
istration were noted in either group. 
Discussion
This study represents the first randomized clinical trial
of T3 repletion in infants during CPB.16 Although the cur-
rent study groups are small, the limited variance within
these populations with regard to age and operative diag-
noses enabled detection of significant differences in spe-
cific hemodynamic parameters between infants who
received either T3 supplementation or placebo. These
patient numbers also enabled some determination of the
T3-repletion pharmacokinetics in this population. 
T4 undergoes peripheral deiodination to T3, which
promotes both immediate and long-term actions on
the cardiovascular system. Results from several previ-
ous studies performed in older patients have implied
that abnormalities in the thyroxine metabolic pathway
exist after CPB. Deficits in conversion, T4 to T3, may
contribute to reductions in circulating T3.4 This con-
tention is supported by studies that demonstrated
increased and nonphysiologic circulating levels of
Fig 1.  Mean serum thyroid hormone concentrations (±SE) in response to CPB for patients receiving T3 (T3) and
control (NT). Time points represent just before the start of CPB and hours after termination of CPB. 
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reverse T3, an inactive T4 metabolite, after CPB in
children and adults.5,17,18 Thus, several investigators
have suggested T3 repletion as a method to restore
thyroid hormone homeostasis and T3 levels in these
clinical situations after CPB.3,16
Previous studies have shown that total T3 blood con-
centrations are reduced in infants after CPB.7 However,
this reduction could be caused by deficits in serum thy-
roid binding capacity that have been observed postop-
eratively in infants and children.5,6,19 Although protein
binding affinity for T3 is less than for T4, free T3 corre-
lates better with this hormone’s actions than total T3.
The current study confirms results from at least one
previous investigation, which indicated that free T3 lev-
els are indeed depressed in infants and remain low for
at least 72 hours.6 These T3 repletion studies demon-
strate that the deaminases that degrade T3 are conserved
after CPB in infants.
Nevertheless, the serum half-life for exogenous T3,
approximately 16 hours, is longer than the 7-hour value
reported for an older population of children (17-78
months) supplemented after CPB for Fontan proce-
dures.18 Additionally, Klemperer and associates3
showed a comparatively more rapid decline in T3 levels
after discontinuing supplementation in adults. The
longer half-life in infants likely represents a matura-
tional difference in either T3 production or metabolism,
as well as in the response of these to CPB. These mat-
urational differences in T3 pharmacokinetics will
require consideration when alternative dosing strate-
gies are being developed, such as repeat bolus or con-
stant infusion, necessary to maintain steady-state T3
levels after CPB. 
Cardiovascular function can be improved by eleva-
tion of circulating thyroid hormone levels in various
pathologic states. T3 repletion or supplementation pro-
duces improvements in contractile function after CPB,8
as well as in dilated cardiomyopathy.20 In the current
study, elevation in heart rate corresponded temporally
to transient elevation in T3 levels. Systemic blood pres-
sure was sustained during this chronotropic response,
thus producing during one time interval an elevation in
peak systolic PRP, an index that correlates with the rate
of myocardial oxygen consumption.21,22 Elevation in
this index implies, though it does not prove, that
increases in cardiac output occurred in these infants.
This remains a subject for future investigation. 
Fig 2.  Heart rate after CPB for the patients receiving T3 (T)
and control patients (NT). Time indicates hours after termi-
nation of CPB. Significant differences between groups occur
at 1 and 3 hours after CPB. 
Fig 3.  Systolic and diastolic pressures for the 2 groups. No
significant differences occur between the 2 groups. NTP,
Control; TP, T3 depleted; s, systolic; d, diastolic. 
Fig 4.  PRP (peak systolic arterial pressure × heart rate) after
CPB in T3-repleted (T) and control patients (NT). 
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The T3-induced chronotropy has not been previous-
ly reported in adults after CPB and might occur
specifically in infants and children. In adults and in
mature animals, immediate actions of T3 occur pre-
dominantly at peripheral resistance vessels, resulting
in vasodilation and decreases in systemic vascular
resistance.20,23 However, enhancement of load-inde-
pendent parameters has also been identified, which
implies that an inotropic effect also occurs.3,8,23 The
heart rate response in infants might reflect matura-
tional changes in the actions of the thyroid. Thyroid
hormone specifically increases β-receptor number
and sensitivity in developing myocardium.10 Thus,
the T3-induced heart rate response might reflect
altered sensitivity to the inotropic agents used in
these infants. 
This study represents the initial phase in evaluation
of T3 repletion in infants after CPB. Further investiga-
tions are required to define the hemodynamic and
metabolic responses to T3 repletion, as well as appro-
priate dosing strategies. However, the data link some
hemodynamic parameters after CPB to free T3 levels in
the blood. T3-induced elevations in these parameters
occurred in patients who underwent relatively short
aortic crossclamp times during surgery, thus minimiz-
ing the level of cardiac contractile depression induced
by operative ischemia. T3 repletion after a more severe
insult might produce more dramatic results. 
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